Syndax Pharmaceuticals Aktie

11,10 EUR -0,20 EUR -1,77 %

01.04.2025

STU

12,13 USD +0,12 USD +0,96 %

nachbörslich01.04.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.1,05 Mrd. EUR

Div. Rendite0,00%

WKNA2AFL6

ISINUS87164F1057

SymbolSNDX

Syndax Pharmaceuticals Aktien News

Sortieren:Datum Meistgelesen

25.07.23PR NewswireSyndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023

24.07.23PR NewswireSyndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

07.07.23PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

02.06.23PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

24.05.23PR NewswireSyndax Announces Participation at Two Upcoming Investor Conferences

09.05.23finanzen.netSyndax Pharmaceuticals: Das sind die jüngsten Quartalszahlen

08.05.23PR NewswireSyndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

04.05.23PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

01.05.23PR NewswireSyndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023

13.04.23PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

07.04.23PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

30.03.23PR NewswireSyndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development

15.03.23PR NewswireSyndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients

06.03.23PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

01.03.23finanzen.netSyndax Pharmaceuticals informierte über die jüngsten Quartalsergebnisse

28.02.23PR NewswireSyndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update

27.02.23PR NewswireSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

27.02.23finanzen.netAusblick: Syndax Pharmaceuticals informiert über die jüngsten Quartalsergebnisse

21.02.23PR NewswireSyndax to Announce Fourth Quarter and Year-end 2022 Financial Results and Host Conference Call and Webcast on February 28, 2023

14.02.23PR NewswireSyndax Announces Participation at Upcoming Investor Conferences

04.01.23PR NewswireSyndax Announces Presentation at 41st Annual J.P. Morgan Healthcare Conference

10.12.22PR NewswireSyndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting

08.12.22PR NewswireSyndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

05.12.22PR NewswireSyndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia

05.12.22PR NewswireSyndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

02.12.22PR NewswireSyndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer

21.11.22PR NewswireSyndax Announces Participation at Evercore ISI Annual HealthCONx Conference

04.11.22finanzen.netSyndax Pharmaceuticals hat die Zahlen zum jüngsten Quartal vorgelegt

03.11.22PR NewswireSyndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update

03.11.22PR NewswireSyndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias

02.11.22finanzen.netAusblick: Syndax Pharmaceuticals stellt Zahlen zum jüngsten Quartal vor

27.10.22PR NewswireSyndax to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022

09.08.22finanzen.netSyndax Pharmaceuticals präsentierte Quartalsergebnisse

08.08.22PR NewswireSyndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update

07.08.22finanzen.netAusblick: Syndax Pharmaceuticals stellt Zahlen zum jüngsten Quartal vor

02.08.22PR NewswireSyndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022

16.06.22PR NewswireSyndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

13.06.22PR NewswireSyndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer

26.05.22PR NewswireSyndax Announces Participation at Two Upcoming Investor Conferences

11.05.22PR NewswireSyndax Announces Participation at Citi's Biopharma Virtual Co-Panel Day

Syndax Pharmaceuticals News

Syndax Pharmaceuticals News: auf dieser Seite finden Sie alle Syndax Pharmaceuticals News und Nachrichten zur Syndax Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Syndax Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Syndax Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.